On 19 December 2018 AddLife signed an agreement on the acquisition of Wellspect HealthCare’s business in the surgery and respiration product areas. The acquisition has been completed and becomes effective as of today, 30 April 2019.
AddLife is acquiring a range of market-leading niche products with associated rights and customer agreements on several geographic markets. The deal means that AddLife is making further inroads in new geographic markets. The business has net sales of around EUR 17 million, with eight markets in Europe and Australia accounting for more than 90 percent of sales. It will primarily be integrated into AddLife’s subsidiaries Mediplast and Biomedica.
Stockholm 30 April 2019
AddLife AB (publ.)
For further information, please contact
Kristina Willgård, CEO, AddLife AB, +46-705 10 12 23
Lars-Erik Rydell, Business Area Manager Medtech, AddLife AB, +46 709 46 48 77
AddLife is an independent player in Life Science that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region. AddLife has around 900 employees in around 40 subsidiaries that operate under their own brands. The Group has net sales of around SEK 2.5 billion. AddLife shares are listed on NASDAQ Stockholm.
This information was submitted for publication on 30 April 2019 at 13:00 CET.